Category: Pharmaceuticals

  • Johnson & Johnson Valuation – April 2019 #JNJ

    Johnson & Johnson Valuation – April 2019 #JNJ

    Johnson & Johnson does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • Bristol-Myers Squibb Co Valuation – April 2019 #BMY

    Bristol-Myers Squibb Co Valuation – April 2019 #BMY

    Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio.

  • Biogen Inc Valuation – March 2019 #BIIB

    Biogen Inc Valuation – March 2019 #BIIB

    Biogen Inc qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.

  • Mylan NV Valuation – March 2019 #MYL

    Mylan NV Valuation – March 2019 #MYL

    Mylan NV does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history.

  • Celgene Corp Valuation – March 2019 #CELG

    Celgene Corp Valuation – March 2019 #CELG

    Celgene Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

  • Amgen Inc Valuation – March 2019 #AMGN

    Amgen Inc Valuation – March 2019 #AMGN

    Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

  • AbbVie Inc Valuation – March 2019 #ABBV

    AbbVie Inc Valuation – March 2019 #ABBV

    AbbVie Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PB ratio.

  • Allergan PLC Valuation – February 2019 $AGN

    Allergan PLC Valuation – February 2019 $AGN

    Allergan plc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg ratio.

  • Incyte Corp Valuation – February 2019 $INCY

    Incyte Corp Valuation – February 2019 $INCY

    Incyte Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN

    Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN

    Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.